Sinonasal Mucormycosis: A to Z

Singh, Vakil; Bansal, Chetan; Kaintura, Madhuri

doi:10.1007/s12070-018-1384-6

Cited by 33 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent multicentre study from India reported that 77% of ROCM cases were in the diabetic population [ 6 ]. Different case series focussed on ROCM cases from India reported diabetes as a risk factor in 80–100% of cases [ 51 , 52 , 53 , 54 , 55 , 56 ]. Trauma is a risk factor for the ROCM type (15–52%), mainly after unhygienic dental procedures during tooth extraction [ 5 , 6 , 57 , 58 ].…”

Section: Clinical Forms Of Mucormycosismentioning

confidence: 99%

Epidemiology of Mucormycosis in India

2021

View full text Add to dashboard Cite

Mucormycosis is an angioinvasive disease caused by saprophytic fungi of the order Mucorales. The exact incidence of mucormycosis in India is unknown due to the lack of population-based studies. The estimated prevalence of mucormycosis is around 70 times higher in India than that in global data. Diabetes mellitus is the most common risk factor, followed by haematological malignancy and solid-organ transplant. Patients with postpulmonary tuberculosis and chronic kidney disease are at additional risk of developing mucormycosis in this country. Trauma is a risk factor for cutaneous mucormycosis. Isolated renal mucormycosis in an immunocompetent host is a unique entity in India. Though Rhizopus arrhizus is the most common etiological agent of mucormycosis in this country, infections due to Rhizopus microsporus, Rhizopus homothallicus, and Apophysomyces variabilis are rising. Occasionally, Saksenaea erythrospora, Mucor irregularis, and Thamnostylum lucknowense are isolated. Though awareness of the disease has increased among treating physicians, disease-associated morbidity and mortality are still high, as patients seek medical attention late in the disease process and given the low affordability for therapy. In conclusion, the rise in the number of cases, the emergence of new risk factors and causative agents, and the challenges in managing the disease are important concerns with mucormycosis in India.

show abstract

Section: Clinical Forms Of Mucormycosismentioning

confidence: 99%

Epidemiology of Mucormycosis in India

2021

View full text Add to dashboard Cite

show abstract

“…Two drugs approved for primary therapy are amphotericin B and isavuconazole while posaconazole can be used for salvage treatment in patients intolerant to Amphotericin B. 19 S. aureus and P. aeruginosa are two bacteria known to make a strong biofilm that maintains the chronic infection impairing the healing of the wound and increasing the development of antibiotic resistance. 20 Thus, invasive infections known or suspected to be due to P. aeruginosa should be empirically started with at least two antipseudomonal agents from different classes till culture sensitivity report is available.…”

Section: Discussionmentioning

confidence: 99%

A rare case of aggressive invasive fungal sinusitis with multidrug resistant Pseudomonas aeruginosa co-infection in immunocompromised: a therapeutic challenge

Basu

Kumar

Gupta

et al. 2021

Int J Otorhinolaryngol Head Neck Surg

View full text Add to dashboard Cite

Mucormycosis is known to be rapidly progressing and fulminant fungal infection which has the ability to cause significant morbidity and mortality, especially in immunocompromised patients. Pseudomonas aeruginosa commonly co-isolated bacterial species from chronic wounds are likely to interact and compete with Mucorales spores.We report a 70 years old female who presented to us initially with left facial swelling with a cheek ulcer. She had initially denied the necessary investigations but later presented to us with flared up symptoms. She was a known case of type 2 diabetes mellitus, hypothyroidism and dilated cardiomyopathy on medication with permanent pacemaker implant. She was found to have left maxillary mucormycosis with left sided cheek wound having superinfection with Pseudomonas aeruginosa. Patient was started on injection Amphotericin B (lipophilic) and injection colistin with surgical debridement of the wound. Left Caldwell-Luc surgery with left inferior meatal antrostomy was performed for clearing fungal debris in left maxillary sinus. The purpose behind this paper is to highlight the need of early detection and aggressive management for successful management of mucormycosis.

show abstract

“…The first step in diagnosing C-ROCM is to conduct a diagnostic nasal endoscopy (DNE) and obtain nasal tissue or nasal scrapings from the affected area. 25 , 26 Tissue biopsies constitute the best specimen for the diagnosis of mucormycosis ( Fig. 1 ) .…”

Section: How To Diagnose Mucormycosis?mentioning

confidence: 99%

COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee)

Malhotra

Gupta

Mehrotra

et al. 2021

Journal of Oral Biology and Craniofacial Research

View full text Add to dashboard Cite

Even before the onslaught of COVID-19 pandemic could settle, the unprecedented rise in cases with COVID-19 associated mucormycosis has pushed the medical health to the fringe. Hyperglycaemia and corticosteroids appear to be the most consistent associations leading to the commonest manifestation of mucormycosis, Rhino-Orbito-Cerebral Mucormycosis. To address challenges right from categorisation and staging of the disease to the management of relentless progression, a multi-disciplinary expert committee was formed to handle the task in an evidence-based format to enforce best practices. The report of the committee on one hand attempts to succinctly present the currently available evidence while at the other also attempts to bridge the evidence-deficient gaps with the specialty-specific virtuosity of experts.

show abstract

Sinonasal Mucormycosis: A to Z

Cited by 33 publications

References 19 publications

Epidemiology of Mucormycosis in India

Epidemiology of Mucormycosis in India

A rare case of aggressive invasive fungal sinusitis with multidrug resistant Pseudomonas aeruginosa co-infection in immunocompromised: a therapeutic challenge

COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee)

Contact Info

Product

Resources

About